Future of Drug Discovery

In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research.  The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months and eight million dollars is roughly what it takes to produce the data package for a single Phase 3 trial. Hill Research is doing that work with one person, in...

This episode is a discussion between ⁠ Rahmad Akbar , Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠ , Co-Founder and CEO of Antiverse ⁠. You will learn: The impact antibody design has on the world. How AI is helping to push antibody design forward, bringing new therapies to patients. What will antibody design look like in the future? Rahmad's LinkedIn page . Rah...

This episode is a discussion between Paul Essery , Host of ' The Tech Business Podcast ' and Murat Tunaboylu Co-Founder and CEO of Antiverse . You will learn: The CEO journey and how Antiverse was founded. How artificial intelligence is solving challenging targets in antibody discovery. Successes and challenges of being a biotech founder (+advice for aspiring entrepreneurs). Be sure to lik...

In this episode, we speak with ⁠⁠ Björn Schimmöller , Co-Founder and CEO of iuvantium , a synthetic immunobiology company developing new modalities for the next generation of immunotherapies. Host: ⁠⁠Murat Tunaboylu⁠⁠ , Co-Founder and CEO of Antiverse . You will learn: The founding journey of iuvantium from Oxford University. How Iuvantium is enhancing immune system efficiency and reducing clinica...

In this episode, we speak with ⁠ Ashwini Ghogare ⁠ , Head of Artificial Intelligence and Automation in Drug Discovery at  ⁠MilliporeSigma⁠ , the Global Science and Technology Group at ⁠Merck⁠ . Host: ⁠Murat Tunaboylu⁠ , Co-Founder and CEO of Antiverse. You will learn: About Ashwini’s journey to her current role. How to bridge the gaps between working groups with different skill sets for optimal co...

In this talk, Murat speaks with   Ming (Tommy) Tang ,  Director of Computational Biology at  Immunitas Therapeutics , an immuno-oncology start-up developing novel therapeutics for patients with cancer.  Tommy is a strong leader and communicator in the field of computational biology. He has dedicated his life's work to accelerating cancer research, with prominent expertise in analysing large-scale...

In this talk, Murat speaks with   ⁠ Nikhil Podduturi ⁠ , Head of Data Science at the Digital Lab of ⁠ Boehringer Ingelheim ⁠ - ⁠ (BI X) ⁠ .    Nikhil co-leads the laboratory and data science chapters at the BI X headquarters in Germany and China. The team at BI X is pioneering digital innovations to improve the lives of patients and animals. The current technologies developed by BI X include PetPr...

In this talk, Murat speaks with   Abhishek Pandey , Principle Research Scientist and Pharma Discovery Group Lead  at AbbVie .  Abhishek currently leads RAIDERS , a Pharma Discovery group integrating machine learning across all of AbbVie's working groups to augment drug discovery capabilities. Abhishek's groups work spans cheminformatics, imaging research, multi-omics, as well as the computation be...

In this talk, Murat speaks with Tzvika Hartman , Senior Vice President of Computation at Biolojic Design , a company curating AI-designed antibodies focused on autoimmune diseases and immuno-oncology applications.  Biolojic uses machine learning to design 'programmable' antibodies with more precise molecular effects. These antibodies work dynamically with their environment, both temporally and spa...

In this captivating podcast series, we dive deep into the world of computational antibody discovery with Ben Holland, our Co-Founder and CTO at Antiverse⁠ . Join us as we uncover the immense potential of merging computational and experimental techniques in the pursuit of revolutionary antibodies, as Ben sheds light on the strong benefits and formidable challenges encountered when targeting complex...

Are you curious about the latest advancements in AI-enabled antibody discovery? In this podcast series, we dive into the world of Antiverse - we are accelerating drug discovery against difficult targets, including GPCRs and ion channels, using machine learning and phage display techniques. Join us as we discuss our mission to target cancer, cardiovascular disease, and other challenging conditions....

In this episode, we speak with Alan Nafiev , Co-Founder and CEO of ‘ RECEPTOR.AI ’ , an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets. Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and serv...

Arctoris COO Tom Fleming talks about automation and building a small molecule discovery platform

In this episode, our guest Assistant Prof. Tim Jenkins talks about snakebites and how to use AI to design broadly neutralising antibodies against venoms. Tim takes us through his experience at Milner Therapeutics Institute and shares his passion and vision for connecting academia and startups/industry players. In the second half of this talk, Tim explains the complexity in the venom domain and the...

In episode 4, Murat talks with Andrew C. R. Martin , Professor of Bioinformatics and Computational Biology at UCL, about abYsis (a fully integrated antibody discovery system) and the latest antibody developability tools! Following the origin story of abYsis, you will hear the differences between the public and commercial versions such as data persistence and security, as well as new tools such as...

Future of Drug Discovery Episode #3 In this session, Murat talks with  Konrad Krawczyk , Assistant Professor SDU and Founder of  NaturalAntibody .  We will be covering Mr Natural Antibody's views on developing and using bioinformatics tools to analyse and discover biologics. Other topics in this episode: - Changing role of bioinformatics from assisting to being the main driver in biologics discove...

In this episode, Murat talks with Ryan Kelly about Abveris (employee #3) and how to run 100+ discovery campaigns against challenging targets.

FODD 1 - Victor Greiff - Immunology and Machine Learning Applied to Drug Discovery